ProductsDispensing a Bright Future
With a team of 150+ finest manufacturing and quality professionals from across the country, we are currently building a portfolio of complex generics including an NDA portfolio comprising long-acting forms of already approved USFDA drugs in therapeutic areas resolving several clearly established key patient compliance and adherence challenges associated with the present standard of care.
